The evidence for Cannabidiol is building
Cannabidiol has been licensed as an add-on treatment for seizures caused by tuberous sclerosis complex for patients aged 2 years and over. Clinical trial evidence shows that it reduces seizure frequency and increases seizure-free days compared to a placebo. While the cost-effectiveness estimates are uncertain, the benefits of reducing the severity of seizures and lowering the risk of sudden unexpected death in epilepsy make it an appropriate use of NHS resources. Therefore, it is recommended as a treatment option by NICE.
Recent Posts
Risicoverevening Policy Updates: Key Amendments for 2022-2025 Explained
On December 9, 2025, the Board of Directors of Zorginstituut Nederland (decision reference 2025027072) approved amendments to the Beleidsregels risicoverevening for 2022, 2023, 2024, and 2025. These changes, published in Staatscourant 2026 nr. 967 on January 19, 2026, correct te...
Characterizing Burnout in Health Professionals: Insights from the BEATS Study in Portugal
Burnout Health Professionals: Join the BEATS Study Call
Burnout health professionals in Portugal are invited to participate in the BEATS study, an initiative by the Portuguese Laboratory for Healthy Work Environments. Titled "B...
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investments and Trends
Latin America Pharma Growth is surging as a high-growth engine for Boehringer Ingelheim, with double-digit market expansions outpacing mature regions like Europe, according to D...